ES2354286T3 - Cristal de un compuesto de indol que contiene sulfonamida y procedimiento de producción del mismo. - Google Patents

Cristal de un compuesto de indol que contiene sulfonamida y procedimiento de producción del mismo. Download PDF

Info

Publication number
ES2354286T3
ES2354286T3 ES04772605T ES04772605T ES2354286T3 ES 2354286 T3 ES2354286 T3 ES 2354286T3 ES 04772605 T ES04772605 T ES 04772605T ES 04772605 T ES04772605 T ES 04772605T ES 2354286 T3 ES2354286 T3 ES 2354286T3
Authority
ES
Spain
Prior art keywords
cyano
indol
crystals
crystalline form
peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04772605T
Other languages
English (en)
Spanish (es)
Inventor
Keiko Takahashi
Kenji Hayashi
Taichi Abe
Takao Omae
Takashi Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Application granted granted Critical
Publication of ES2354286T3 publication Critical patent/ES2354286T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
ES04772605T 2003-09-10 2004-09-01 Cristal de un compuesto de indol que contiene sulfonamida y procedimiento de producción del mismo. Expired - Lifetime ES2354286T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003318953 2003-09-10
JP2003-318953 2003-09-10

Publications (1)

Publication Number Publication Date
ES2354286T3 true ES2354286T3 (es) 2011-03-11

Family

ID=34308544

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04772605T Expired - Lifetime ES2354286T3 (es) 2003-09-10 2004-09-01 Cristal de un compuesto de indol que contiene sulfonamida y procedimiento de producción del mismo.

Country Status (24)

Country Link
US (2) US7754894B2 (enExample)
EP (1) EP1666463B1 (enExample)
JP (1) JP4435090B2 (enExample)
KR (1) KR20060120644A (enExample)
CN (2) CN101165049A (enExample)
AT (1) ATE486849T1 (enExample)
AU (1) AU2004272400B2 (enExample)
BR (1) BRPI0414314A (enExample)
CA (1) CA2536995C (enExample)
CY (1) CY1110975T1 (enExample)
DE (1) DE602004029907D1 (enExample)
DK (1) DK1666463T3 (enExample)
ES (1) ES2354286T3 (enExample)
HR (1) HRP20100631T1 (enExample)
IL (2) IL174059A0 (enExample)
MX (1) MXPA06002732A (enExample)
NO (1) NO335256B1 (enExample)
NZ (1) NZ546111A (enExample)
PL (1) PL1666463T3 (enExample)
PT (1) PT1666463E (enExample)
RU (1) RU2336269C2 (enExample)
SI (1) SI1666463T1 (enExample)
TW (1) TW200514770A (enExample)
WO (1) WO2005026118A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3868534B2 (ja) * 1996-05-24 2007-01-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド誘導体の製造法および中間体
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
ES2341843T3 (es) * 2000-02-03 2010-06-29 EISAI R&D MANAGEMENT CO., LTD. Inhibidores de la expresion de integrina.
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Also Published As

Publication number Publication date
WO2005026118A1 (ja) 2005-03-24
CN100406440C (zh) 2008-07-30
DK1666463T3 (da) 2010-12-20
TWI349663B (enExample) 2011-10-01
CY1110975T1 (el) 2015-06-11
NO20061545L (no) 2006-06-09
EP1666463B1 (en) 2010-11-03
HRP20100631T1 (hr) 2010-12-31
CA2536995C (en) 2013-12-17
EP1666463A1 (en) 2006-06-07
TW200514770A (en) 2005-05-01
KR20060120644A (ko) 2006-11-27
AU2004272400A1 (en) 2005-03-24
ATE486849T1 (de) 2010-11-15
PL1666463T3 (pl) 2011-04-29
BRPI0414314A (pt) 2006-10-31
NO335256B1 (no) 2014-10-27
RU2006111454A (ru) 2006-08-27
JPWO2005026118A1 (ja) 2007-11-08
DE602004029907D1 (de) 2010-12-16
PT1666463E (pt) 2011-01-17
IL174059A0 (en) 2006-08-01
US7754894B2 (en) 2010-07-13
US20090247768A1 (en) 2009-10-01
AU2004272400B2 (en) 2010-03-04
US20070082941A1 (en) 2007-04-12
CN1849305A (zh) 2006-10-18
IL196569A0 (en) 2011-07-31
EP1666463A4 (en) 2007-12-12
HK1092796A1 (en) 2007-02-16
MXPA06002732A (es) 2006-06-05
CA2536995A1 (en) 2005-03-24
NZ546111A (en) 2008-11-28
JP4435090B2 (ja) 2010-03-17
CN101165049A (zh) 2008-04-23
SI1666463T1 (sl) 2011-02-28
RU2336269C2 (ru) 2008-10-20

Similar Documents

Publication Publication Date Title
ES2772498T3 (es) Preparación de un inhibidor mek y formulación que comprende el mismo
ES3034158T3 (en) Novel salt of terphenyl compound
ES2985167T3 (es) Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respiratorios
ES2375841T3 (es) Nueva forma cristalina de un derivado de piridazino[4,5-b]indol.
WO2022188889A1 (zh) 作为parp7抑制剂的化合物
ES2554360T3 (es) Bencenosulfonato de 2-[[[2-[(hidroxiacetil)amino]-4-piridinil]metil]tio]-n-[4 (trifluorometoxi)fenil]-3-piridincarboxamida, cristales del mismo, polimorfos del mismo y procesos para la producción del mismo
TW202308991A (zh) 三苯化合物之固體形式
ES2317856T3 (es) Analogos de bencimidazol sustituido con homopiperidinilo como relajantes gastricos.
CN108727343A (zh) 含有3-氨基四氢吡咯的喹唑啉酮类parp-1/2抑制剂及其制备方法、药物组合物和用途
WO2013131465A1 (zh) N-(4-(3-氟苄氧基)-3-氯苯基)-6-(5-((2-(甲基亚砜基)乙基氨基)甲基)-2-呋喃基)-喹唑啉-4-胺二甲苯磺酸盐的多晶型物及其制备方法和用途
ES2354286T3 (es) Cristal de un compuesto de indol que contiene sulfonamida y procedimiento de producción del mismo.
JP2020533412A (ja) ２−（５−（４−（２−モルホリノエトキシ）フェニル）ピリジン−２−イル）−ｎ−ベンジルアセトアミドの固体形態
ES2240215T3 (es) Nuevas formas polimorfas de olanzapina.
KR20070112381A (ko) 5-[2-아미노-4-(2-푸릴)피리미딘-5-일]-1-메틸피리딘-2(1ｈ)-온의 결정 및 그 제조 방법
ES2315898T3 (es) Derivados de carbamato de 2h- o 3h-benzo(e)inzadol-1-ilo, su preparacion y su aplicacion en terapeutica.
JP2018002644A (ja) （Ｓ）−Ｎ−（４−アミノ−５−（キノリン−３−イル）−６，７，８，９−テトラヒドロピリミド［５，４−ｂ］インドリジン−８−イル）アクリルアミドの結晶
JP7282787B2 (ja) ピラゾロ［３，４－ｄ］ピリミジンの結晶
HK1092796B (en) Crystal of sulfonamide-containing indole compound and process for producing the same
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
CN102666528A (zh) 晶体cdc7 抑制剂盐
CN101175751B (zh) 具有哌啶环的吲哚衍生物的晶体和其制备方法
JP2009286694A (ja) ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶
HK40041642A (en) Crystal of pyrazolo[3,4-d]pyrimidine
WO2019232663A1 (zh) 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物